Orladeyo, BioCryst's main revenue source, saw impressive growth in 2024, but faces significant competition. Click here to ...

The current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...

Q4 2024 Earnings Call Transcript February 24, 2025 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., ...

ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)——FY 2025 ORLADEYO ...

Zurich: Takeda has announced that the European Medicines Agency (EMA) has given approval for an additional 2 mL pre-filled ...

DiaMedica Therapeutics (DMAC) announced the peer-reviewed publication entitled: “Recombinant human tissue kallikrein-1 for treating acute ...

CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...

The article describes the mechanism of action of DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1, and its scientific rationale in the Company’s ongoing Phase 2/3 ...

ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)- -FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 mil ...